ScripAntibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin
ScripOctober ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P
ScripIambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage